Forte Biosciences, Inc.

Forte Biosciences reported positive Phase 1b clinical results for FB102, its investigational therapy targeting vitiligo, under Regulation FD and Item 8.01. The study demonstrated a meaningful reduction in depigmentation area and acceptable tolerability in treated patients. Vitiligo represents a significant unmet medical need with limited approved systemic options, making a positive Phase 1b read a potentially material catalyst. The company intends to discuss next steps for the program, including potential Phase 2 trial design, in upcoming investor communications.

Forte Biosciences filed Amendment No. 1 to its Form S-3 shelf registration statement (Reg. No. 333-296425) on June 5, 2026, amending the original June 2, 2026 registration to incorporate required updates or corrections for SEC effectiveness. The S-3 registers securities for potential future issuance on a delayed or continuous basis under Rule 415, but does not represent a commitment to any specific offering. This is a procedural amendment filing; the company remains a smaller reporting company. No specific offering terms, share counts, or use-of-proceeds were disclosed.

Forte Biosciences filed an original Form S-3 shelf registration statement on June 2, 2026, registering an unspecified amount of securities for future issuance on a delayed or continuous basis under Rule 415. The S-3 covers potential future offerings of common stock, preferred stock, warrants, and/or units. The registration does not commit the company to any specific offering and will only become effective upon SEC review and declaration. The shelf registration provides financial flexibility for future capital raises as Forte advances its FB102 vitiligo program.

Forte Biosciences held its 2026 Annual Meeting of Stockholders on May 29, 2026, with shareholder voting results reported under Items 5.02 and 5.07. Shareholders approved the further amendment and restatement of the 2021 Equity Incentive Plan, increasing total authorized shares to 5,190,000 (adding 1,850,000 newly requested shares to the prior 3,340,000 approved in January 2025). The plan covers grants of stock options, RSUs, and performance awards to employees, directors, and consultants. The equity plan expansion provides Forte with additional share-based compensation capacity as it advances its Phase 1b vitiligo program.